BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Revlimid lenalidomide: Phase III started

Celgene and Groupe d'Etude des Lymphomes de l'Adulte (GELA) began the open-label, international Phase III RELEVANCE trial to compare Revlimid plus rituximab vs. rituximab plus chemotherapy in up to 1,000 patients with newly diagnosed follicular lymphoma. Celgene markets Revlimid to treat relapsed...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >